The analysis of circulating cell free DNA is an important tool for the analysis of tumor resistance, tumor heterogeneity, detection of minimal residual disease and detection of allograft rejection in kidney or heart transplant patients. The proper use of this technique is important, and starts with considering pre-analytic aspects. The current paper addresses some important technical considerations to ensure the proper and harmonized use of cfDNA techniques.

What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA

Del Re, Marzia;
2021-01-01

Abstract

The analysis of circulating cell free DNA is an important tool for the analysis of tumor resistance, tumor heterogeneity, detection of minimal residual disease and detection of allograft rejection in kidney or heart transplant patients. The proper use of this technique is important, and starts with considering pre-analytic aspects. The current paper addresses some important technical considerations to ensure the proper and harmonized use of cfDNA techniques.
2021
cfDNA
ctDNA
Liquid biopsy
NCSLC
pre-analytical factors
Technical aspects
Biomarkers
Tumor
Diagnostic Tests
Routine
Humans
Neoplasm
Residual
Cell-Free Nucleic Acids
Circulating Tumor DNA
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0009898121001893-main.pdf

non disponibili

Licenza: Dominio pubblico
Dimensione 332.71 kB
Formato Adobe PDF
332.71 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14245/8992
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 26
social impact